The effect of neighborhood socioeconomic disadvantage on smoking status, quit attempts, and receipt of cessation support among adults with cancer: Results from nine ECOG‐ACRIN Cancer Research Group trials
Year: 2023
Type: article
Abstract: BACKGROUND: Tobacco use is associated with adverse outcomes among patients diagnosed with cancer. Socioeconomic determinants influence access and utilization of tobacco treatment; little is known about the relationship between neighborhood socioeconomic disadvantage (NSD) and tobacco assessment, assistance, and cessation among patients diagnosed with cancer. METHODS: A modified Cancer Patient Tobacco Use Questionnaire (C-TUQ) was administered to patients enrolled in nine ECOG-ACRIN clinical trials. We examined associations of NSD with (1) smoking status, (2) receiving tobacco cessation assessment and support, and (3) cessation behaviors. NSD was classified by tertiles of the Area Deprivation Index. Associations between NSD and tobacco variables were evaluated using logistic regression. RESULTS: A total of 740 patients completing the C-TUQ were 70% male, 94% White, 3% Hispanic, mean age 58.8 years. Cancer diagnoses included leukemia 263 (36%), lymphoma 141 (19%), prostate 131 (18%), breast 79 (11%), melanoma 69 (9%), myeloma 53 (7%), and head and neck 4 (0.5%). A total of 402 (54%) never smoked, 257 (35%) had formerly smoked, and 81 (11%) were currently smoking. Patients in high disadvantaged neighborhoods were approximately four times more likely to report current smoking (odds ratio [OR], 3.57; 95% CI, 1.69-7.54; p = .0009), and more likely to report being asked about smoking (OR, 4.24; 95% CI, 1.64-10.98; p = .0029), but less likely to report receiving counseling (OR, 0.11; 95% CI, 0.02-0.58; p = .0086) versus those in the least disadvantaged neighborhoods. CONCLUSIONS: Greater neighborhood socioeconomic disadvantage was associated with smoking but less cessation support. Increased cessation support in cancer care is needed, particularly for patients from disadvantaged neighborhoods.
Source: Cancer
DOI: 10.1002/cncr.35039
Authors: Angela Wangari Walter, Ju‐Whei Lee, Joanna M. Streck, Ilana F. Gareen, Benjamin A. Herman, Sheetal M. Kircher, Ruth C. Carlos, Shaji K. Kumar, Ingrid A. Mayer, Nabil F. Saba, Timothy S. Fenske, Joel W. Neal, Michael B. Atkins, Frank S. Hodi, Christos E. Kyriakopoulos, Clare M. Tempany‐Afdhal, Tait D. Shanafelt, Lynne I. Wagner, Stephanie R. Land, Jamie S. Ostroff, Elyse R. Park
Institutions: University of Massachusetts Lowell, Dana-Farber Cancer Institute, Harvard University, Massachusetts General Hospital, Brown University, Northwestern University, University of Michigan, U-M Rogel Cancer Center, Mayo Clinic, Vanderbilt University, AstraZeneca (United States), Emory University, Winship Cancer Institute, Medical College of Wisconsin, Stanford Cancer Institute, Stanford University, Georgetown Lombardi Comprehensive Cancer Center, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Brigham and Women's Hospital, University of North Carolina at Chapel Hill, National Cancer Institute, Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,740
Awards: G1881030900, ECOG-ACRIN Network Group Operations Center, G1946161885, G2819266960, G3100437649, G3475623468, Network Lead Academic Participating Site: Memorial Sloan Kettering Cancer Center, G4102770861, G4188603810, G4340946455, ECOG-ACRIN NCORP Research Base, NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care, G5881529110, G6705915398, G6952446453, G7313980898, G7768533534, G8220656038, Vanderbilt Network Lead Academic Participating Site for the NCTN, National Clinical Trials Network Research at the University of Wisconsin, National Capital Area (NCA) Minority/Underserved NCORP, G9000003249, G9000174216, G9000280145, G9000319834, G9000327439, G9000339569, Cancer Center Support Grant
OpenAlex ID: W4387356830